These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21912922)

  • 1. Impact of adopting minimum inhibitory concentration as the determinant of susceptibility to cephalosporins and carbapenems in multi-drug resistant Enterobacteriaceae.
    Parta M
    Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):975-80. PubMed ID: 21912922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
    Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Jean SS; Lee WS; Yu KW; Liao CH; Hsu CW; Chang FY; Ko WC; Chen RJ; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Lam C; Liu CY; Hsueh PR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):969-976. PubMed ID: 25661253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
    Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
    Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
    Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
    Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
    J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
    Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Hu Z; Chu Y; Chen S; Cao B; Su J; Gui B; Duan Q; Zhang S; Shao H; Kong H; Badal RE; Xu Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):245-51. PubMed ID: 26482308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.
    Kohner PC; Robberts FJ; Cockerill FR; Patel R
    J Clin Microbiol; 2009 Aug; 47(8):2419-25. PubMed ID: 19494061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.
    Bork JT; Heil EL; Leekha S; Fowler RC; Hanson ND; Majumdar A; Johnson JK
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):328-333. PubMed ID: 29031525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome analysis of enterobacteriaceae with non-wild type susceptibility to third-generation cephalosporins recovered from diseased dogs and cats in Europe.
    Pepin-Puget L; El Garch F; Bertrand X; Valot B; Hocquet D
    Vet Microbiol; 2020 Mar; 242():108601. PubMed ID: 32122604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibility to first-generation Cephalosporins in Enterobacteriaceae isolated from urine culture according to CLSI and EUCAST breakpoints].
    Corvalán V; Hervé B; Sanhueza C; Martínez N; Almonacid M; Fuente S
    Rev Chilena Infectol; 2018; 35(3):329-331. PubMed ID: 30534916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
    Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
    Nijssen S; Florijn A; Bonten MJ; Schmitz FJ; Verhoef J; Fluit AC
    Int J Antimicrob Agents; 2004 Dec; 24(6):585-91. PubMed ID: 15555882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.